勒沃庫森，2020年8月3日－拜耳將其動物保健業務部門出售予與美國企業Elanco Animal Health Incorporated。二家公司是於去年八月簽署此項協議，此項交易於包括主管機關核可等各項條件達成後正式完成。
交易完成後，拜耳在扣除常規購買價調整後獲得51.7億美元（税前）現金，以及7,290萬股Elanco Animal Health普通股，相當於該公司已發行股票的15.5％。拜耳仍計畫在適當時候撤出對Elanco的股權，保留持股一段期間，直至2021年中。
“我們要感謝動物保健部門同仁一直以來的貢獻及其為拜耳帶來的成功，我們為動物保健業務找到了一個強大的新東家–Elanco，這項交易也造就了全球動物保健事業領域的領導品牌之一。”拜耳集團董事會主席沃納·鮑曼(Werner Baumann)說，“我們也成功地維護了員工利益。” 據與Elanco達成的協議，所有拜耳動物保健員工都享有至少一年的僱用保護免受被單方終止僱用關係，以及類似或不低於總體之福利保障。
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com.
Elanco Animal Health (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we’re driven by our vision of Food and Companionship Enriching life and our Elanco Healthy Purpose™ CSR framework – all to advance the health of animals, people and the planet. Learn more at www.elanco.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.